Showing results (191-200 of 266) with videos related to
Sort By:
Pageof 27
Molecular Imaging and Biology|March 3, 2025
Spatial FAP Expression as Detected by 68 Ga-FAPI-46 Identifies Myofibroblasts Beyond the Infarct Scar After ReperfusionAnnika Hess, Alexandra Renko, Andreas Schäfer, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|September 10, 2016
Evaluation of 68Ga-Glutamate Carboxypeptidase II Ligand Positron Emission Tomography for Clinical Molecular Imaging of Atherosclerotic Plaque NeovascularizationThorsten Derlin, Johannes Thiele, Desiree Weiberg, et al.Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|April 30, 2024
Heart-brain axis: Pushing the boundaries of cardiovascular molecular imagingMaria Khalil, Hui Chong Lau, James T Thackeray, et al.European Journal of Nuclear Medicine and Molecular Imaging|November 6, 2008
Rubidium-82 PET-CT for quantitative assessment of myocardial blood flow: validation in a canine model of coronary artery stenosisRiikka Lautamäki, Richard T George, Kakuya Kitagawa, et al.European Journal of Nuclear Medicine and Molecular Imaging|October 31, 2020
Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancerSazan Rasul, Markus Hartenbach, Tim Wollenweber, et al.Journal of the American College of Cardiology|March 21, 2007
Role of imaging in cardiac stem cell therapySaskia L M A Beeres, Frank M Bengel, Jozef Bartunek, et al.Annals of Nuclear Medicine|November 11, 2020
18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphomaThorsten Derlin, Christian Schultze-Florey, Rudolf A Werner, et al.Cancers|June 2, 2021
Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate CancerSazan Rasul, Tim Wollenweber, Lucia Zisser, et al.Nuclear Medicine Communications|September 19, 2022
Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastasesLucia Zisser, Josef Yu, André Oszwald, et al.International Journal of Radiation Oncology, Biology, Physics|September 12, 2018
Patterns of Progression AfterAlexander Soldatov, Christoph A J von Klot, Daniel Walacides, et al.Pageof 27